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Summary Chronic obstructive pulmonary disease (COPD) ranks fourth as a cause
of death in the United States, behind heart disease, cancer, and stroke. Addition-
ally, since serious co-morbidities are often present in patients with COPD, many
die from other diseases such as cardiac disease or cancer. Not surprisingly, mul-
tiple factors, reflective of both respiratory disease process and the substantial
co-morbidity, predict survival in the disease. As might be expected, physiologic
derangements such as airflow obstruction, hypoxemia, lung hyperinflation, and
exercise capacity predict survival in COPD. Anemia, cachexia and reductions in
lean body mass also relate to prognosis. Perhaps less recognized is the more recent
documentation that more subjective assessments, such as dyspnea and health re-
lated quality of life, are also important predictors of survival. The integration of
some of the most important of these variables may provide a more comprehensive
evaluation of disease severity. For example, a validated multi-dimensional dis-
ease rating that includes the body mass index (B), degree of airflow obstruction
(O), dyspnea (D), and exercise capacity (E) (BODE Index) is capable of predicting
COPD-related hospitalization and mortality more than its individual components.
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Mortality in COPD
Since individuals with COPD are at substantial risk
for serious co-morbidity such as cardiovascular dis-
ease and cancer, it is perhaps not surprising they
frequently die with their disease, not from it. De-
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pending on the characteristics of the samples stud-
ied, about 1/3 to 1/2 or more of deaths are due to
causes other than COPD. These findings undoubtedly
point toward co-morbidity, which is pervasive in this
population. Some of the factors related to survival
in COPD are discussed below.
Markers for Mortality in COPD
Forced expiratory volume in 1 second (FEV1)
Although no single physiologic measure can capture
the multiple factors that elevate the risk for mortal-
ity in patients with COPD, the diminished FEV1 has
a long-established association with increased mor-
tality in this disease. For example, in the Intermit-
tent Positive Pressure Breathing (IPPB) trial, the pa-
tient' s age and initial FEV1 values were the most ac-
curate predictors of mortality in 985 patients with
COPD who were followed for 3 years.1 FEV1 has long
been used in COPD as the principal variable deter-
mining the presence of disease, its severity, and the
response to different modalities of treatment.2
Cigarette smoking is without doubt the pri-
mary etiologic factor for COPD. Therefore, lifestyle
changes, principally, smoking cessation, can reduce
the accelerated decline in FEV1 seen in suscepti-
ble patients, to the average to age-adjusted normal
decline.3,4 Nonetheless, in some susceptible smok-
ers who quit, FEV1 levels still decline after smoking
cessation at an accelerated rate for reasons that re-
main obscure.
Pharmacologic intervention with long-acting in-
haled bronchodilators, either alone5 or combined
with inhaled corticosteroids6 can result in sustained
improvements in FEV1 by more than 15% for up to
1 year. Such findings have prompted large pharma-
cological trials with outcomes such as survival that
have provided us with very valuable information7.
Bilateral lung volume reduction (LVR), a surgical
technique reserved for patients with severe hetero-
geneous emphysema, may improve FEV1 by almost
79% 6 months after the procedure.8 Further in some
selected patients with upper lobe emphysema and
poor exercise capacity after rehabilitation, LVR can
also improve survival.9 The improvement in FEV1 ob-
served with single-lung transplantation can be as
high as 231% and for bilateral-lung transplantation
is 498%. It is thus possible to improve the degree of
airflow limitation associated with this disease and
concomitantly observe an improvement in survival.
In those studies, the association of changes in sur-
vival as an outcome is loosely related to the change
in FEV1.
Lung hyperinflation
Severe hyperinflation is a recognizable character-
istic of COPD expressed on the physical exam
by the barrel-shaped chest seen in patients with
emphysema.10 In normal individuals, exercise pro-
duces tidal volume increases secondary to both in-
creased end-inspiratory lung volume and reductions
in end-expiratory lung volume or functional resid-
ual capacity. In COPD, by contrast, patients display
increases in end-expiratory lung volume with ex-
ercise, therefore reducing inspiratory capacity and
causing end-inspiratory lung volume to approach to-
tal lung capacity. Static hyperinflation represents a
permanent elevation in end-expiratory lung volume,
caused by changes in the elastic or recoil properties
of the lungs that trigger increasing lung volumes.
Some evidence supports the use of hyperinflation
as a surrogate marker for mortality in COPD. For
example, the relationship between lung hyperinfla-
tion, measured as the ratio of inspiratory capacity
to total lung capacity or IC/TLC, and mortality in
689 patients (95% males) with COPD, was an im-
portant independent predictor of mortality after 34
months of follow-up. The increase in mortality be-
came critical for an IC/TLC ratio below 25% (critical
hyperinflation).11 There is now accumulating evi-
dence that hyperinflation can be effectively treated
with pharmaco-therapeutic agents12 and even more
effectively with lung volume reduction surgery. 8
Pulmonary cachexia
Weight loss is prevalent among patients with COPD,
and has emerged as an independent risk factor for
its mortality.13,14 The impact of weight change on
outcomes in COPD was examined retrospectively in
400 COPD patients who had not received nutritional
therapy, and in a prospective post hoc analysis of
203 COPD patients who received nutritional support
alone or in combination with anabolic steroids.15
In the retrospective portion of the study, low body
mass index (BMI) (<25 kg/m2) was associated with
a significant increase in the risk for mortality (P <
0.001). In a multivariate analysis of the prospective
data, weight gain (>2 kg/8 wks) was a significant
predictor of survival.15 Although more evidence is
needed before universal recommendations may be
made, weight change can be considered an indepen-
dent and modifiable risk factor for mortality in pa-
tients with COPD that also deserves survelliance.15
Anemia
Anemia in COPD patients may be more prevalent
than expected, affecting 10% to 15% of patients
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suffering from severe forms of the disease.16 In
a study of 2,524 COPD patients who were pre-
scribed long-term oxygen therapy, 12.6% of males
and 8.2% of females were identified as anemic.17
Recently, a linear correlation was identified be-
tween hemoglobin levels and mortality in a co-
hort that included 700 patients with COPD.18 Ane-
mia --- hemoglobin < 12.9 g/dl --- was present in
116 (17%) patients. Anemic patients had a signifi-
cantly higher Medical Research Council (MRC) score,
a lower 6-minute walk distance (6MWD) and a higher
mortality than non anemic patients. These differ-
ences remained significant when controlling for the
relevant demographic, physiologic, and disease co-
variates in regression analyses, where anemia was
an independent predictor of the above outcomes.
Other investigators have found anemia to be as-
sociated with poor outcomes in COPD.17,19 Anemia
may accompany disease chronicity and inflamma-
tion in COPD and contribute to poor exercise per-
formance because of its association with worsen-
ing dyspnea, possibly due to a decrease in oxygen
delivery. It is intuitive although remains unknown
whether alleviating anemia in patients with COPD
will lead to improved outcomes and reduced mor-
tality.
Exercise capacity
Exercise capacity, measured by the 6MWD test, has
been significantly correlated with mortality in pa-
tients with COPD.20 The 6MWD test has established
reliability and validity in predicting survival in a
variety of settings, including post-pulmonary reha-
bilitation and after lung-volume---reduction surgery
(LVRS).20 In 198 predominantly male patients (83%)
with severe COPD who were followed for 2 years,
survival increased progressively with increases in
the 6MWD, when distances were divided into dis-
crete 100-meter increments (Figure 1). Further-
more, the 6MWD test was a better predictor of mor-
tality than FEV1 and BMI. Importantly, the decline
in 6MWD occurred independently of changes in FEV1
indicating that both are possibly measuring differ-
ent domains of the disease and could be considered
complementary.
Several treatment approaches improve exercise
capacity in patients with COPD. In 1,218 patients
with severe emphysema, LVRS resulted in signifi-
cantly greater improvements in exercise capacity
after 24 months, compared with standard medi-
cal care.9 Further, in patients with predominantly
upper-lobe emphysema and diminished exercise ca-
pacity, significant reductions in mortality were seen
in those who underwent LVRS. In contrast, patients
with non---upper-lobe emphysema and high exercise
Figure 1 Mortality progressively decreases as the 6-
minute walk distance (6MWD) test score increases (P <
0.0001, by Chi-squared analysis). For distances < 100 m,
n = 19; for 101---200 m, n = 61; for 201---300 m, n = 57; for
301---400 m, n = 46; and for > 400 m, n = 15.18 Reprinted
with permission from Eur Respir J. Copyright 2004, Eu-
ropean Respiratory Society.
capacity experienced an increase in mortality in as-
sociation with surgery.
Although less consistent than for the 6MWD, phar-
macological treatments have also been shown to
improve exercise endurance measured using a con-
stant load exercise protocol during a formal cardio-
pulmonary exercise test.21,22
Dyspnea
Dyspnea, the most fundamental and debilitating
symptom of COPD should be routinely evaluated and
considered in conjunction with pulmonary function
when evaluating COPD. Pharmacological treatment
with different agents and using different dyspnea
scales have consistently shown to improve breath-
lessness in patients with COPD.21,23 Pulmonary reha-
bilitation also is highly effective at decreasing dys-
pnea among COPD patients.24
Dyspnea has also been found to be predictive of
survival in COPD. In a 5-year, prospective, multi-
center trial of 227 patients with COPD,25 survival
rate was not significantly linked to COPD staging
based on FEV1. Rather, dyspnea as measured using
the Medical Research Council dyspnea questionnaire
did predict survival (P < 0.001).
Quality of life, functional status, and activity level
Quality of life is a personal, subjective entity that
it difficult to fully portray. However, health-related
quality of life (HRQL), focusing on those aspects of
quality of life affected by the disease and its treat-
ment, is easier to quantify. The measurement of
HRQL allows us to obtain a better picture of how
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patients are affected by their illness. Assessment in
subjective areas such as dyspnea and HRQL provides
complementary information to physiologic measure-
ments. For example, there is only a weak associ-
ation between the level of dyspnea and degree of
airway obstruction in COPD, and changes in dyspnea
can occur without documented changes in the FEV1.
While there is an association between physiologic
measures and HRQL, other factors influence the in-
dividual' s perception of this subjective variable. In
COPD, these include symptoms, activity levels, so-
cial factors, emotional state, recreational factors
and sleep.
There is frequently confusion over terminology in
the measurement of dyspnea, HRQL, and functional
status in COPD. For example, some dyspnea mea-
sures rate the symptom of breathlessness through
its limitation on activity. Furthermore, activity level
(also referred to as functional status) is an impor-
tant component of questionnaire-rated HRQL mea-
surement: it is generally either a major component
or one of several domains of the instrument. Finally,
walk tests or tests of exercise endurance have often
been used as surrogate measures of overall activity
levels.
Lower HRQL has been associated with mortality
and morbidity in COPD. However, the considerable
overlap (and confusion) among dyspnea, functional
status, activity levels, and HRQL makes it difficult
to determine just what components of this complex
variable influence survival.
Oga et al.26 studied 144 male COPD patients
for 5 years. Most (64.5%) of the mortality over
this period was due to respiratory related causes,
yet the HRQL scores on two respiratory-specific in-
struments, the Saint George' s Respiratory Question-
naire (SGRQ) and the Chronic Respiratory Disease
Questionnaire (CRQ) were not different at baseline
among those who survived from those who died.
Domingo-Salvany et al.27 evaluated survival (us-
ing Cox multivariate hazard analysis) in 321 male
COPD patients for over 7 years. Less than 50% of
the 106 deaths were from respiratory causes. They
determined that worse lung function, greater age,
lower BMI and poorer HRQL (measured by the SGRQ)
or poor physical function levels (physical component
of SF-36) were predictive of respiratory-related
mortality.
Martinez et al.28 reported on mortality in 609
COPD patients enrolled in the medical arm of the
National Emphysema Treatment Trial-NETT, 64.2% of
whom were male. Median follow up was 3.9 years
with a total mortality rate of 12.7%. Using multi-
variate hazard ratio, the modified BODE, followed
by exercise test stress test and 6 MWD were high-
est predictors of mortality (HR ≥ 2). A multivariate
analysis was also undertaken using two models, one
with the individual components of the BODE (model
1) and one (model 2) with a modified BODE index
(substituting the MRC with the UCSD SOBQ). In the
first model, age, oxygen use, RV (% pred), exer-
cise workload, difference in percent of emphysema
upper lung:lower lung (UL:LL), and perfusion ratio
were significant. The SGRQ was not predictive of
mortality and the SOBQ was not significantly related
to mortality. In model 2, the model remained es-
sentially the same with the only additional variable
contributing being diffusion capacity, hemoglobin
and the modified BODE. The greatest ratios (HR ≥
1.74) in both cases was the difference in percent-
age of emphysema (UL:LL) and age (HR ≥ 1.64).
Fan et al29 followed 3,282 males with COPD
over one year; their mortality rate was 5.1% (n =
106). HRQL was measured using the Seattle Obstruc-
tive Lung Disease Questionnaire (SOLDQ),30 and the
physical (PCS) and mental health (MCS) components
of the Short-Form-36 questionnaire (SF-36). Overall,
the odds ratio was highest for the lowest quartiles,
with the physical domain of the SOLDQ demonstrat-
ing the highest (OR > 6) risk for mortality than the
other measures (OR < 4.5). The multivariate logis-
tic regression model included other variables (age,
steroid use, comorbidities, and prior hospitaliza-
tion). In this model, only the physical component of
the SOLDQ was a risk factor for mortality (OR from
highest 2.9 to 5.7 lowest quartile).
In summary, the evaluation of HRQL in COPD pa-
tients following treatment or in predicting mortal-
ity, the area which has seemed to be overlooked
as a predictor, is the activity level of the patient.
Whether measured by exercise stress test, walk dis-
tance or as a major or minor component of a HRQOL
measure, the activity level of the patient is an im-
portant factor in understanding COPD patients.
How should we measure activity levels in the fu-
ture? We have shown that when a functional status
measure or subscore of functional status in a HRQL
measure is included in the analysis, the activity
component contributes to mortality. In some cases
this contribution exceeds many other domains, in-
cluding well accepted physiologic measures (DLCO),
or co morbidities (BMI). Evaluation of the specific
contribution of functional status in either domains
of HRQL measures, or disease specific functional
status measures should be an important area of
measurement focus in future studies. It should no
longer be sufficient to report a total score as these
minimize the potential contribution of the domains,
such as functional status, of these questionnaires.
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Methodological problems in predicting
survival in COPD
Many of the variables predicting survival in univari-
ate analyses are inter-related. For example, the
relationships between age and degree of airway
obstruction with mortality are strong. This should
come as no surprise as both advancing age and the
degree of airway obstruction are associated with
mortality. Because of this, analysis of factors pre-
dicting survival should consider controlling for age
and FEV1. Additionally, most studies of mortality in
COPD patients were of male subjects, which histori-
cally, has been the major gender affected by COPD.
Given the increase in numbers of females diagnosed
with COPD, an effort should be made to include fe-
male subjects in studies.
Many studies did not analyze separately those
subjects dying from respiratory related deaths from
those dying from other causes (e.g., lung cancer,
myocardial infarction). To understand the effects of
COPD on mortality, greater control should be made
in analyzing respiratory causes of mortality from
non respiratory causes. To make progress in care of
patients with COPD, we must be cautious in our re-
search methods, to clearly identify new directions.
In multivariate analyses to date, relatively few
factors have withstood the rigor of predicting mor-
tality in COPD patients. For instance, using a uni-
variate hazards analysis involving 149 COPD patients
followed by a multi-center consortium of pulmonary
rehabilitation programs,31 variables most related to
survival were the functional status scores on the
Pulmonary Functional Status Scale, and improve-
ment in the six minute walk distance. Significant,
but less strongly predictive of survival was a higher
FEV1. We have reviewed similar published studies
and a summary of the findings from these studies
are presented in Table 1.
Multidimensional staging of COPD and
mortality
COPD is now recognized as a disease with not only
respiratory impairment but one that also has sig-
nificant systemic consequences. In this context, it
becomes increasingly important to identify respira-
tory and systemic manifestations of COPD that can
effectively signal an increased risk for mortality.
Similarly, it would be important to identify which
of these variables may serve as surrogates for out-
comes. The recognition and modification of likely
surrogates for mortality may provide an early oppor-
tunity to ameliorate morbidity and improve survival.
If several variables predict mortality independently,
it is logical that a multidimensional tool that incor-
porates several of these variables should be able to
provide a more comprehensive evaluation of a pa-
tient' s compromise and hence it' s clinical staging.
As accumulating evidence suggests that multiple
factors can be associated with mortality in COPD,
it is reasonable that a composite index may pro-
vide a practical way to more comprehensively eval-
uate patients with COPD. Celli and colleagues eval-
uated 207 patients with COPD and identified 4 eas-
ily measured variables that predicted an elevated
risk for death: BMI (B), degree of airflow obstruc-
tion (O), dyspnea as measured by the MRC dyspnea
scale (D), and exercise capacity (E) as measured by
the 6MWD test.32 These variables were used to con-
struct a multidimensional scale, the BODE index,
that ranged from 0 (least risk) to 10 (highest risk)
(Table 2).
The BODE index was prospectively validated in
a separate cohort of 625 predominantly male pa-
tients with COPD who were evaluated every 3 to 6
months for at least 2 years, or until death.32 The
results indicated that each quartile increase in the
BODE Index score yielded an increase in the risk for
mortality (Figure 2). In fact, quartile 4 (BODE Index
score of 7 to 10) was associated with a mortality
rate of 80% at 52 months. The BODE Index predicted
mortality more accurately than the FEV1 (Figure 2).
In a preliminary study that included 720 patients
(93% male) with COPD, the BODE Index has also been
shown to correlate well with measures of quality
of life, as assessed by the St. George' s Respiratory
Questionnaire (SGRQ). The highest correlation was
seen between BODE total scores and the activity
component of the SGRQ. The overall correlation be-
tween BODE and SGRQ was r = 0.58; P < 0.0001. The
SGRQ scores increased as BODE quartiles increased.
In univariate analysis both tools predicted survival
in COPD.33
Furthermore, in clinical studies comparing the
BODE Index with FEV1, the BODE Index was shown
to better assess progression of disease secondary to
COPD exacerbation,34 and to be a significantly bet-
ter predictor than the FEV1 for the risk for hospital-
ization due to exacerbations.35
Pulmonary rehabilitation has become an integral
component of the standard of care in the compre-
hensive management of COPD36,37,? Pulmonary reha-
bilitation is known to improve several of the surro-
gate markers for mortality in COPD, namely dysp-
nea and exercise capacity. Based on this, Cote et
al explored the hypothesis that pulmonary rehabil-
itation would lessen the severity of COPD and the
risk for mortality, as measured by the BODE Index.39
In this study, of the 246 patients who qualified
for and were offered rehabilitation, 116 accepted
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Table 1 Predictors of survival in COPD patients using multivariate analysis
Cox Hazard Analysis (HR) Logistic Regression (OR)
Study Oga et al Domingo-Salvany et al Martinez et al Fan et al
Subjects n = 144 n = 312 n = 609 n = 3,282
Respir. COD (%) 64.5% *45.3% NA NA NA
Males(%) 100% 100% 64.2% 96.3%
Variables SGRQ SF-36 w/o BODE BODE
Age 1.13 1.59 1.65 1.64 1.72 1.50
FEV1 0.94 2.32 2.38 NS 
RV % pred.    1.57 1.56 
Diff % emphysema    1.74 1.80 
TLC % pred.    0.68 NS 
CPET    1.54 1.48 
Perfusion ratio    1.57 1.53 
DLCO NS   NS 1.36 
Hemoglobin    NS 1.38 
↓PaO2    NS NS 
↑PaCO2    NS NS 
O2 use    1.46 NS 
Peak VO2 NS     
Co-morbidity      2.00
Smoking Hx NS   NS NS adj
Steroid use NS     1.80
BMI NS 0.69 0.68 NS 
6MWT    NS 
BODE     1.48 
Self-report tools
SF-36 PCS  1.40   NS
SGRQ total 1.035 1.36 NS NS 
CRQ total NS     
CRQ dyspnea NS     
CRQ fatigue NS     
UCSD SOBQ    NS 
SOLDQ-Physical      
51---75th      2.90
26---50th      3.20
0---26th      5.70
COD = cause of death; RV = residual volume; BMI = body mass index; CPET = cardio pulmonary exercise testing;
6MWD = six minute walk distance; SGRQ = Saint George Respiratory Questionnaire; UCSD SOBQ = UC San Diego
shortness of breath questionnaire; SOLDQ = Seattle Obstructive Lung Disease Questionnaire; Adj = analysis
adjusted for that variable; * analysis reported in those who died due to a respiratory cause;  = not used in
study; shaded cells = variable a component of BODE; TLC = total lung capacity; Dlco= diffusion capacity; Diff
%emphysema = difference in emphysema upper lung : lower lung; SF-36 = Medical Outcomes Study short form
36; CRQ = Chronic Respiratory Questionnaire; BODE = BODE index (BMI, airflow obstruction [FEV1], dyspnea
[UCSD SOBQ], exercise capacity [6 minute walk]); NS = non significant; NA = not addressed.
and completed the 8-week, 3-times weekly rehabil-
itation program; 130 declined for reasons that re-
main unclear. The change in BODE scores were com-
pared between rehabilitation program participants
and non participants.
At baseline, BODE Index scores were in the 3rd
and 4th quartiles for 75% (n = 83) of the patients
in this cohort (98% male). Patients were followed
for more than 2 years or until death. During that
time, approximately 30% of the patients who partic-
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Figure 2 Kaplan---Meier Survival Curves for the Four Quartiles of the body mass index, degree of airflow obstruc-
tion, dyspnea, and Exercise Capacity Index (BODE; Panel A) and the Three Stages of Severity of Chronic Obstructive
Pulmonary Disease as defined by the American Thoracic Society (ATS; Panel B). In Panel A, quartile 1 is a score of 0
to 2, quartile 2 is a score of 3 to 4, quartile 3 a score of 5 to 6, and quartile 4 a score of 7 to 10. Survival differed
significantly among the 4 groups (P < 0.001 by the log-rank test). In Panel B, Stage I is defined by a forced expiratory
volume in 1 second (FEV1) that is more than 50% of the predicted value, Stage II by an FEV1 that is 36% to 50% of the
predicted value, and Stage III by an FEV1 that is no more than 35% of the predicted value. Survival differed signifi-
cantly among the 3 groups (P < 0.001 by the log-rank test).28 # = number at risk. Reprinted with permission from N
Engl J Med. Copyright 2004, Massachusetts Medical Society.
Table 2 Calculation of the BODE index. Points from
each variable are added according to the threshold
value measured for each one. The value ranges from
0 to a maximum of 10
BODE Score
Variable 0 1 2 3
FEV1, % predicted >65 50---65 35---49 <35
Dyspnea: MRC 0---1 2 3 4
6MWD meters >350 250---349 150---249 <149
BMI >21 <21
FEV1 = forced expiratory volume in 1 second; MRC =
Medical Research Council; 6MWD = 6-minute walk
distance test; BMI = body mass index.
ipated in rehabilitation continued exercise training
3 times weekly for the entire 2-year period. After
pulmonary rehabilitation, 71% of those participating
in the 2 year PR program had improved their BODE
Index scores by at least 1 point, with 25% improving
by 2 points (Figure 3).
The patients in the PR group had an initial BODE
Index of 5.07, which decreased significantly to 4.18
after PR (month 3). Patients in this group shifted
from the 3rd quartile to 2nd quartile, and their ini-
tially predicted mortality of 20% to 30% changed to
an observed mortality of 11.2%. Patients in the non-
PR group had a BODE Index entry of 6.94 (approach-
ing BODE 4th quartile), and in this group there was
Figure 3 Distribution of the change in BODE Index
in all patients completing pulmonary rehabilitation (3
months). Improvement in the BODE score is manifested
by decreases in the index, whereas an increase in the
value implies worsening in the prognosis. More than 70%
of the patients had an improvement of at least 1 unit
in the BODE Index.35 Reprinted with permission from Eur
Respir J. Copyright 2005, European Respiratory Society.
almost a 20% worsening of BODE Index over time.
This group of patients had the highest mortality rate
(50%) (Figure 4).
These data suggest that the BODE Index changes
not only reflect the global changes due to PR, but
may also imply a change in outcome, suggesting
that the BODE Index can be considered a surrogate
marker for mortality.39 For patients who responded
to pulmonary rehabilitation, defined as an improve-
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Figure 4 All-cause and respiratory mortality at 2 years
in patients with no pulmonary rehabilitation (PR; purple
bars), PR nonresponder patients (blue bars), and PR re-
sponder patients (red bars).35 Reprinted with permission
from Eur Respir J. Copyright 2005, European Respiratory
Society.
ment in the BODE Index score of at least 1 point,
BODE Index scores improved by a statistically signif-
icant 25% at 3 months, compared with the patients
who did not respond to rehabilitation. These im-
provements in BODE Index scores were maintained
for a full 2 years after the start of pulmonary re-
habilitation, while patients who did not participate
in pulmonary rehabilitation displayed an 18% dete-
rioration in BODE Index scores.39 Thus, the BODE In-
dex may be a useful tool in predicting survival in
patients with severe COPD who participate in pul-
monary rehabilitation programs.
Finally, a recent study by Imfeld and colleagues
explored the change in the BODE index after lung
volume reduction in 186 patients that had the pro-
cedure and were followed for a period of close to
60 months.40 LVRS resulted in improvement in BODE
scores with the mean value decreasing from 7.1 to 4
units 6 months after surgery, thus proving that BODE
does respond to intervention. More importantly, the
change in BODE at 6 months was a predictor of sub-
sequent survival, thus suggesting that the change in
BODE can be used an outcome measure.
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